Biopharmaceutical products need to continually evolve to become more effect treatments for patients. Biosimilars, biobetters, and ADCs are important biologics that researchers study. However, they all pose their own particular production and analysis challenges. This phase focuses on analysis techniques to confirm similarities between the biosimilar and originator molecule, manufacturing and the regulatory issues surrounding biobetters, and methods for characterizing mAbs and therapeutic proteins.